Drugs facing NCE-1 in 2026

1. List of Amvuttra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US9370581 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US10806791 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US11286486 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

US10683501 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

US10208307 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

CN102006890A ALNYLAM PHARMS INC Targeting Lipid
Oct, 2015

(7 years ago)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 13, 2027

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

2. List of Baxdela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9539250 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(2 years from now)

US8273892 MELINTA Salt and crystalline forms thereof of a drug
Aug, 2026

(3 years from now)

US8871938 MELINTA Process for making quinolone compounds
Sep, 2029

(6 years from now)

USRE46617 MELINTA Process for making quinolone compounds
Dec, 2029

(6 years from now)

US7728143 MELINTA Salt and crystalline forms thereof of a drug
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648093 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(2 years from now)

US8969569 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(2 years from now)

US8252813 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2026

(3 years from now)

US9750822 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US8410077 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9200088 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US7635773 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9493582 MELINTA Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 19, 2022
New Indication (I) Oct 24, 2022
Generating Antibiotic Incentives Now (GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

3. List of Bludigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11499050 PROVEPHARM SAS NA
Dec, 2037

(14 years from now)

US10927258 PROVEPHARM SAS Process for the preparation of Indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 8, 2027

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: July, 2026

Market Authorisation Date: 08 July, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

4. List of Camzyos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9181200 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2027

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: April, 2026

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

More Information on Dosage

5. List of Cibinqo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 14, 2027

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: January, 2026

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage

6. List of Cresemba drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(2 years from now)

US10812238 ASTELLAS Configurable reference signals
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Sep, 2027

(4 years from now)

US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 6, 2022
New Chemical Entity Exclusivity (NCE) Mar 6, 2020
Generating Antibiotic Incentives Now (GAIN) Mar 6, 2027

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: March, 2026

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

7. List of Elucirem drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114863 GUERBET Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
Sep, 2028

(5 years from now)

US10973934 GUERBET Gadolinium bearing PCTA-based contrast agents
Aug, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

8. List of Lytgobi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(10 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 30, 2027

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET;ORAL

More Information on Dosage

9. List of Mounjaro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(8 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(8 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

10. List of Omlonti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648097 SANTEN Pyridylaminoacetic acid compound
Oct, 2029

(6 years from now)

US10774072 SANTEN Crystal of N-substituted sulfonamide compound
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986 SANTEN Medical composition for treatment or prophylaxis of glaucoma
Oct, 2029

(6 years from now)

US10702511 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10765750 SANTEN Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10179127 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US11197849 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US9415038 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

USRE48183 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

11. List of Pluvicto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10406240 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(5 years from now)

US11318121 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(5 years from now)

US10398791 AAA USA NOVARTIS Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: March, 2026

Market Authorisation Date: 23 March, 2022

Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

12. List of Pyrukynd drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785450 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(8 years from now)

US11254652 AGIOS PHARMS INC Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Nov, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632114 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(9 years from now)

US9682080 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(9 years from now)

US9980961 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(9 years from now)

US9193701 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Oct, 2032

(9 years from now)

US11234976 AGIOS PHARMS INC Methods of using pyruvate kinase activators
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 17, 2027

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg

Dosage: TABLET;ORAL

More Information on Dosage

13. List of Quviviq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732075 IDORSIA Benzimidazole-proline derivatives
Jun, 2033

(10 years from now)

US9790208 IDORSIA Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10023560 IDORSIA Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2027

Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient

NCE-1 date: April, 2026

Market Authorisation Date: 07 April, 2022

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage

14. List of Relyvrio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9872865 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(10 years from now)

US11071742 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(10 years from now)

US10251896 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(10 years from now)

US10857162 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2027

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 29 September, 2022

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

15. List of Solosec drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849884 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(12 years from now)

US11324721 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(12 years from now)

US10857133 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(12 years from now)

US10682338 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(12 years from now)

US11000508 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(12 years from now)

US11020377 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(12 years from now)

US11000507 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(12 years from now)

US10335390 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 15, 2022
New Indication (I) Jun 30, 2024
New Patient Population (NPP) Jan 26, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 15, 2027

Drugs and Companies using SECNIDAZOLE ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 15 September, 2017

Treatment: Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of trichomoniasis in patients 12 years of age and older; Treatment of trichomoniasis in adults; Treatment of bacterial vaginosis in adult women

Dosage: GRANULE;ORAL

More Information on Dosage

16. List of Sotyktu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47929 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
Nov, 2033

(10 years from now)

US10000480 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021475 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 9, 2027

Drugs and Companies using DEUCRAVACITINIB ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 09 September, 2022

Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are canididates for systemic therapy or phototherapy

Dosage: TABLET;ORAL

More Information on Dosage

17. List of Vabomere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680136 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007206 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(8 years from now)

US9694025 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(8 years from now)

US10183034 REMPEX Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Aug, 2031

(8 years from now)

US10172874 REMPEX Pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Aug, 2031

(8 years from now)

US10561675 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(8 years from now)

US11376237 REMPEX Methods of treating bacterial infections
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 29, 2022
Generating Antibiotic Incentives Now (GAIN) Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: August, 2026

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, enterobacter cloacae species complex with meropenem & vaborbactam as specified; Treatment of patients 18 years of age and older with complicated urinary tract infections caused by susceptible microorganisms; Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae species complex; Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species complex with meropenem & vaborbactam as specified

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

18. List of Vonjo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8153632 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
Jan, 2029

(5 years from now)

US8980873 CTI BIOPHARMA CORP 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Mar, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9573964 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
May, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 28, 2027

Drugs and Companies using PACRITINIB CITRATE ingredient

NCE-1 date: February, 2026

Market Authorisation Date: 28 February, 2022

Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2); Treatment of myelofibrosis with pacritinib

Dosage: CAPSULE;ORAL

More Information on Dosage

19. List of Vtama drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10647649 DERMAVANT SCI Process for preparing tapinarof
Nov, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458108 DERMAVANT SCI NA
May, 2036

(13 years from now)

US10195160 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(13 years from now)

US10426743 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM;TOPICAL

More Information on Dosage

20. List of Ztalmy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858609 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8022054 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8318714 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8618087 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US9056116 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8367651 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US9029355 MARINUS Solid ganaxolone compositions and methods for the making and use thereof
Nov, 2026

(3 years from now)

US10603308 MARINUS Methods and compositions for treatment of epileptic disorders
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2027

Drugs and Companies using GANAXOLONE ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 01 June, 2022

Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older

Dosage: SUSPENSION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in